

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)—Continued
 [Study eligibility criteria based on Population, Intervention, Comparator, Outcome (PICO), and other elements]

Element	Inclusion criteria	Exclusion criteria
	<p><i>Key Question 2:</i></p> <ul style="list-style-type: none"> • Minimum follow-up <ul style="list-style-type: none"> ○ If population has no CV risk factors (or unselected general population): 10 years ○ If population has one or more CV risk factors: 5 years 	
Setting	<ul style="list-style-type: none"> • General community settings, including nursing homes, assisted living facilities, etc. 	<ul style="list-style-type: none"> • Hospital or other acute care settings. • Institutionalized, confined settings (e.g., prisons).
Publication	<ul style="list-style-type: none"> • English language • Published in peer-reviewed journals 	

* Minimum sample size may be altered depending on the number of eligible studies found.

† Applying this approach for the 2016 AHRQ report n-3 fatty acids and cardiovascular disease (<https://doi.org/10.23970/AHRQPCERTA223>), we included: for cardiac event outcomes, observational studies with at least 10,000 participants; for stroke outcomes, at least 3000 participants; for arrhythmia outcomes, at least 2000 participants; congestive heart failure outcomes, at least 700 participants; and for peripheral vascular disease events and MACE outcomes, at least 500 participants. In all instances, if a study meets eligibility criteria for any outcome, we will extract all outcomes of interest from that study; therefore, there will be multiple instances of studies being included for an outcome even though the study might not have met study size criteria for that specific outcome.

CV = cardiovascular; CVD = cardiovascular disease; PUFA = polyunsaturated fatty acids; ALA = alpha-linolenic acid; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; DPA = docosapentaenoic acid; n-3 = Omega 3; n-6 = Omega 6; FA = fatty acid; c = cholesterol; LDL = low-density lipoprotein; IDL = intermediate-density lipoprotein; HDL = high-density lipoprotein; TC = total cholesterol; Tg = Triglycerides/Triacylglycerols; apoA = apolipoprotein; MAC[C]E = Major adverse cardiac (or cerebro) events; BMI = body mass index; KQ = key question; N = number of participants.

Dated: November 21, 2024.

Marquita Cullom,
Associate Director.

[FR Doc. 2024-27798 Filed 11-26-24; 8:45 am]

BILLING CODE 4160-90-P

Dates: February 19–20, 2025.

Times: 10 a.m.–5 p.m., EST.

Place: Web Conference.

Agenda: To review and evaluate grant applications.

For Further Information Contact:

Carlisha Gentles, Pharm.D., B.C.P.S., C.D.C.E.S., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341. Telephone: (770) 488-1504; Email: CGentles@cdc.gov.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024-27857 Filed 11-26-24; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—CE25-025, Rigorous Evaluation of Community- and Societal-Level Primary Prevention Approaches to Prevent Adverse Childhood Experiences (ACEs): Expanding the Best Available Evidence.

Dates: February 25–26, 2025.

Times: 10 a.m.–5 p.m., EST.

Place: Web Conference.

Agenda: To review and evaluate grant applications.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE25-021, Research Grants for Preventing Violence and Violence Related Injury.